Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.86) EPS for the quarter, beating analysts’ consensus estimates of ($1.31) by $0.45, Zacks reports. The company had revenue of $1.39 million during the quarter, compared to the consensus estimate of $1.40 million. Intelligent Bio Solutions had a negative net margin of 269.28% and a negative return on equity of 145.68%.
Intelligent Bio Solutions Price Performance
Intelligent Bio Solutions stock traded down $0.07 during trading hours on Thursday, hitting $2.03. The company had a trading volume of 5,035 shares, compared to its average volume of 271,747. The firm has a market cap of $6.72 million, a PE ratio of -0.32 and a beta of 4.48. Intelligent Bio Solutions has a one year low of $1.35 and a one year high of $24.90. The firm has a 50-day moving average of $1.81 and a 200 day moving average of $2.87.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Intelligent Bio Solutions in a research note on Thursday, October 15th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Reduce”.
Read Our Latest Research Report on INBS
About Intelligent Bio Solutions
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a life sciences company focused on developing and commercializing non-invasive diagnostic and screening technologies. Its primary product is the Intelligent Bio Solutions Drug Screening System, a portable platform designed to detect drugs of abuse through sweat collected from a person’s fingerprint. The system uses a disposable drug screening cartridge and a handheld reader to analyze fingerprint sweat and provide results rapidly. The company markets the technology for applications such as workplace testing, law enforcement, rehabilitation programs, and other settings that require convenient, observed drug screening.
Read More
- Five stocks we like better than Intelligent Bio Solutions
- CoreWeave’s Backlog Is Surging—Can the Stock Follow?
- Tesla’s Plan to End Cybertruck Reveals Its Real Priorities
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
Receive News & Ratings for Intelligent Bio Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Bio Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
